Post-marketing study design to evaluate the effectiveness of the 9-valent and 4-valent HPV vaccines on serious HPV-related cervical disease in China

The 4-valent (4 v) and 9-valent (9 v) human papillomavirus (HPV) vaccines are approved in China for females aged 9–45 years. However, the real-world impact of 4vHPV or 9vHPV vaccination for the prevention of high-grade cervical disease in Chinese women is lacking. Two post-marketing surveillance stu...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Yu Yang, Liang Zhang, Susanne Hartwig, Peng Jiang, Houyu Zhao, Ruogu Meng, Zhike Liu, Zuoxiang Liu, Keqin Ding, Xuedan You, Carol Koro, Guozhang Xu, Siyan Zhan
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Taylor & Francis Group 2024-12-01
Saila:	Human Vaccines & Immunotherapeutics
Gaiak:	Human papillomavirus vaccine cervical cancer cervical intraepithelial neoplasia Ningbo China
Sarrera elektronikoa:	https://www.tandfonline.com/doi/10.1080/21645515.2024.2418168
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!